NASDAQ:ZLAB Zai Lab (ZLAB) Stock Price, News & Analysis $24.33 -1.17 (-4.59%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$24.15 -0.18 (-0.73%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Zai Lab Stock (NASDAQ:ZLAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zai Lab alerts:Sign Up Key Stats Today's Range$23.71▼$24.8650-Day Range$18.18▼$27.0052-Week Range$15.96▼$34.07Volume951,847 shsAverage Volume788,558 shsMarket Capitalization$2.77 billionP/E RatioN/ADividend YieldN/APrice Target$37.25Consensus RatingModerate Buy Company Overview Zai Lab Ltd. (NASDAQ: ZLAB) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases with significant unmet medical needs. The company’s research and development activities span oncology, autoimmune and inflammatory disorders, infectious diseases, and neuroscience. Founded in 2014 by Samantha Du, Zai Lab has built a portfolio through internal research as well as licensing and collaboration agreements with international pharmaceutical and biotechnology companies. Its products and partnered therapies have included treatments such as ZEJULA (niraparib) for certain ovarian cancers, QINLOCK (ripretinib) for gastrointestinal stromal tumors, and NUZYRA (omadacycline), an antibiotic used to treat certain bacterial infections. Zai Lab has historically concentrated on developing and commercializing innovative therapies in China while expanding its research, development and commercial capabilities internationally. The company’s operations have included activities in China, the United States and other global markets, supported by partnerships intended to broaden access to its medicines. Zai Lab was founded and led by Samantha Du, a biotechnology executive with experience in drug development and company building.AI Generated. May Contain Errors. Read More Zai Lab Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks37th Percentile Overall ScoreZLAB MarketRank™: Zai Lab scored higher than 37% of companies evaluated by MarketBeat, and ranked 678th out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingZai Lab has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialZai Lab has a consensus price target of $37.25, representing about 53.1% upside from its current price of $24.33.Amount of Analyst CoverageZai Lab has only been the subject of 3 research reports in the past 90 days.Read more about Zai Lab's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Zai Lab are expected to decrease in the coming year, from ($2.17) to ($2.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zai Lab is -14.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zai Lab is -14.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZai Lab has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zai Lab's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.54% of the float of Zai Lab has been sold short.Short Interest Ratio / Days to CoverZai Lab has a short interest ratio ("days to cover") of 9.19.Change versus previous monthShort interest in Zai Lab has recently increased by 1.74%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZai Lab does not currently pay a dividend.Dividend GrowthZai Lab does not have a long track record of dividend growth. News and Social Media1.1 / 5News Sentiment-0.26 News SentimentZai Lab has a news sentiment score of -0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Zai Lab this week, compared to 3 articles on an average week. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Zai Lab insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $235,145.00 in company stock.Percentage Held by Insiders4.88% of the stock of Zai Lab is held by insiders.Percentage Held by Institutions41.65% of the stock of Zai Lab is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Zai Lab's insider trading history. Receive ZLAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zai Lab and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZLAB Stock News HeadlinesZai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)September 29, 2026 | marketscreener.comMZai Lab (NASDAQ:ZLAB) Stock Bumped Up to "Hold" by Wall Street ZenSeptember 26, 2026 | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 3 at 1:00 AM | Stansberry Research (Ad)Zai Lab Ltd (ZLAB)September 24, 2026 | in.investing.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 23, 2026 | americanbankingnews.comZai Lab Limited (ZLAB)September 11, 2026 | finance.yahoo.comZ.ai shares surge 8% after releasing new AI model running only on Chinese chipsAugust 26, 2026 | cnbc.comZai Lab: Revenue Growth And Zoci's Upside OptionalityAugust 19, 2026 | seekingalpha.comSee More Headlines ZLAB Stock Analysis - Frequently Asked Questions How have ZLAB shares performed this year? Zai Lab's stock was trading at $17.64 at the beginning of the year. Since then, ZLAB stock has increased by 37.9% and is now trading at $24.33. How were Zai Lab's earnings last quarter? Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) announced its quarterly earnings results on Tuesday, June, 30th. The company reported ($0.50) earnings per share (EPS) for the quarter. The company had revenue of $106.31 million for the quarter. Zai Lab had a negative net margin of 41.86% and a negative trailing twelve-month return on equity of 27.43%. When did Zai Lab IPO? Zai Lab (ZLAB) raised $142 million in an initial public offering on Wednesday, September 20th 2017. The company issued 8,333,333 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO. How do I buy shares of Zai Lab? Shares of ZLAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Zai Lab own? Based on aggregate information from My MarketBeat watchlists, some other companies that Zai Lab investors own include NVIDIA (NVDA), Tesla (TSLA), Intel (INTC), Meta Platforms (META), Advanced Micro Devices (AMD), Baidu (BIDU) and Home Depot (HD). Company Calendar Last Earnings6/30/2026Today10/03/2026Investor update10/23/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ZLAB's financial health is in the Green zone, according to TradeSmith. ZLAB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZLAB CIK1704292 Webwww.zailaboratory.com Phone862161632588Fax86-21-6163-2570Employees1,784Year Founded2014Price Target and Rating Average Price Target for Zai Lab$37.25 High Price Target$45.00 Low Price Target$32.00 Potential Upside/Downside+53.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$175.54 million Net Margins-41.86% Pretax Margin-42.42% Return on Equity-27.43% Return on Assets-16.72% Debt Debt-to-Equity RatioN/A Current Ratio2.13 Quick Ratio1.92 Sales & Book Value Annual Sales$460.16 million Price / Sales6.02 Cash FlowN/A Price / Cash FlowN/A Book Value$6.39 per share Price / Book3.81Miscellaneous Outstanding Shares113,780,000Free Float108,230,000Market Cap$2.77 billion OptionableOptionable Beta0.73 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ZLAB) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zai Lab Limited Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Zai Lab With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
